These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

316 related items for PubMed ID: 8990130

  • 1. Distribution, levels, and activity of glycogen synthase kinase-3 in the Alzheimer disease brain.
    Pei JJ, Tanaka T, Tung YC, Braak E, Iqbal K, Grundke-Iqbal I.
    J Neuropathol Exp Neurol; 1997 Jan; 56(1):70-8. PubMed ID: 8990130
    [Abstract] [Full Text] [Related]

  • 2. Compartmentalized tau hyperphosphorylation and increased levels of kinases in transgenic mice.
    Götz J, Nitsch RM.
    Neuroreport; 2001 Jul 03; 12(9):2007-16. PubMed ID: 11435938
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. The active form of glycogen synthase kinase-3beta is associated with granulovacuolar degeneration in neurons in Alzheimer's disease.
    Leroy K, Boutajangout A, Authelet M, Woodgett JR, Anderton BH, Brion JP.
    Acta Neuropathol; 2002 Feb 03; 103(2):91-9. PubMed ID: 11810173
    [Abstract] [Full Text] [Related]

  • 5. Distribution of active glycogen synthase kinase 3beta (GSK-3beta) in brains staged for Alzheimer disease neurofibrillary changes.
    Pei JJ, Braak E, Braak H, Grundke-Iqbal I, Iqbal K, Winblad B, Cowburn RF.
    J Neuropathol Exp Neurol; 1999 Sep 03; 58(9):1010-9. PubMed ID: 10499443
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Glycogen synthase kinase 3 alteration in Alzheimer disease is related to neurofibrillary tangle formation.
    Baum L, Hansen L, Masliah E, Saitoh T.
    Mol Chem Neuropathol; 1996 Sep 03; 29(2-3):253-61. PubMed ID: 8971700
    [Abstract] [Full Text] [Related]

  • 8. Glycogen synthase kinase-3 is associated with neuronal and glial hyperphosphorylated tau deposits in Alzheimer's disease, Pick's disease, progressive supranuclear palsy and corticobasal degeneration.
    Ferrer I, Barrachina M, Puig B.
    Acta Neuropathol; 2002 Dec 03; 104(6):583-91. PubMed ID: 12410379
    [Abstract] [Full Text] [Related]

  • 9. Increased level of active GSK-3beta in Alzheimer's disease and accumulation in argyrophilic grains and in neurones at different stages of neurofibrillary degeneration.
    Leroy K, Yilmaz Z, Brion JP.
    Neuropathol Appl Neurobiol; 2007 Feb 03; 33(1):43-55. PubMed ID: 17239007
    [Abstract] [Full Text] [Related]

  • 10. Indirubins inhibit glycogen synthase kinase-3 beta and CDK5/p25, two protein kinases involved in abnormal tau phosphorylation in Alzheimer's disease. A property common to most cyclin-dependent kinase inhibitors?
    Leclerc S, Garnier M, Hoessel R, Marko D, Bibb JA, Snyder GL, Greengard P, Biernat J, Wu YZ, Mandelkow EM, Eisenbrand G, Meijer L.
    J Biol Chem; 2001 Jan 05; 276(1):251-60. PubMed ID: 11013232
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Role of protein kinase B in Alzheimer's neurofibrillary pathology.
    Pei JJ, Khatoon S, An WL, Nordlinder M, Tanaka T, Braak H, Tsujio I, Takeda M, Alafuzoff I, Winblad B, Cowburn RF, Grundke-Iqbal I, Iqbal K.
    Acta Neuropathol; 2003 Apr 05; 105(4):381-92. PubMed ID: 12624792
    [Abstract] [Full Text] [Related]

  • 13. Role of protein phosphatase-2A and -1 in the regulation of GSK-3, cdk5 and cdc2 and the phosphorylation of tau in rat forebrain.
    Bennecib M, Gong CX, Grundke-Iqbal I, Iqbal K.
    FEBS Lett; 2000 Nov 17; 485(1):87-93. PubMed ID: 11086171
    [Abstract] [Full Text] [Related]

  • 14. Activation of glycogen synthase kinase-3 induces Alzheimer-like tau hyperphosphorylation in rat hippocampus slices in culture.
    Li X, Lu F, Tian Q, Yang Y, Wang Q, Wang JZ.
    J Neural Transm (Vienna); 2006 Jan 17; 113(1):93-102. PubMed ID: 15959856
    [Abstract] [Full Text] [Related]

  • 15. [GSK-3beta: a central kinase for neurodegenerative diseases?].
    Petit-Paitel A.
    Med Sci (Paris); 2010 May 17; 26(5):516-21. PubMed ID: 20510151
    [Abstract] [Full Text] [Related]

  • 16. Phosphorylation sites on tau identified by nanoelectrospray mass spectrometry: differences in vitro between the mitogen-activated protein kinases ERK2, c-Jun N-terminal kinase and P38, and glycogen synthase kinase-3beta.
    Reynolds CH, Betts JC, Blackstock WP, Nebreda AR, Anderton BH.
    J Neurochem; 2000 Apr 17; 74(4):1587-95. PubMed ID: 10737616
    [Abstract] [Full Text] [Related]

  • 17. Decreased nuclear beta-catenin, tau hyperphosphorylation and neurodegeneration in GSK-3beta conditional transgenic mice.
    Lucas JJ, Hernández F, Gómez-Ramos P, Morán MA, Hen R, Avila J.
    EMBO J; 2001 Jan 15; 20(1-2):27-39. PubMed ID: 11226152
    [Abstract] [Full Text] [Related]

  • 18. Dephosphorylation of abnormal sites of tau factor by protein phosphatases and its implication for Alzheimer's disease.
    Ono T, Yamamoto H, Tashima K, Nakashima H, Okumura E, Yamada K, Hisanaga S, Kishimoto T, Miyakawa T, Miyamoto E.
    Neurochem Int; 1995 Mar 15; 26(3):205-15. PubMed ID: 7787767
    [Abstract] [Full Text] [Related]

  • 19. Role of protein phosphatase 2A in Alzheimer's disease.
    Rudrabhatla P, Pant HC.
    Curr Alzheimer Res; 2011 Sep 15; 8(6):623-32. PubMed ID: 21605044
    [Abstract] [Full Text] [Related]

  • 20. Kinases and phosphatases and tau sites involved in Alzheimer neurofibrillary degeneration.
    Wang JZ, Grundke-Iqbal I, Iqbal K.
    Eur J Neurosci; 2007 Jan 15; 25(1):59-68. PubMed ID: 17241267
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 16.